Tratamiento de mantenimiento con fármacos antipsicóticos para la esquizofrenia
Information
- DOI:
- https://doi.org/10.1002/14651858.CD008016.pub2Copy DOI
- Database:
-
- Cochrane Database of Systematic Reviews
- Version published:
-
- 16 May 2012see what's new
- Type:
-
- Intervention
- Stage:
-
- Review
- Cochrane Editorial Group:
-
Cochrane Schizophrenia Group
- Copyright:
-
- Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Article metrics
Altmetric:
Cited by:
Authors
Contributions of authors
Stefan Leucht: designing the review, study selection, data extraction, statistical analysis and writing of the report.
Magdolna Tardy: designing the review, study selection, data extraction, statistical analysis and writing of the report.
Katja Komossa: designing the study, study selection, data extraction and writing of the report.
Stephan Heres: designing the study, data extraction and writing of the report.
Werner Kissling: designing the study, data extraction and writing of the report.
John Davis: designing the study, data extraction, statistical analysis and writing of the report.
All authors have agreed to a co‐publication of this review in the Lancet (Leucht 2012).
Sources of support
Internal sources
-
Freistaat Bayern, Germany.
-
Psychiatric Institute, University of Chicago at Illinois, USA.
External sources
-
Bundesministerium für Bildung und Forschung Grant number 01KG0816 88166528, Germany.
Declarations of interest
Stefan Leucht: has received honoraria for consulting/advisory boards from Alkermes, Bristol‐Myers Squibb, Eli Lilly, Janssen, Johnson & Johnson, Medavante and Roche; lecture honoraria from AstraZeneca, Bristol‐Myers Squibb, Eli Lilly, Essex Pharma, Janssen, Johnson & Johnson, Lundbeck Institute, Pfizer and Sanofi‐Aventis; and Eli Lilly has provided medication for a trial with SL as the primary investigator.
Magdolna Tardy: none to declare.
Katja Komossa: none to declare.
Stephan Heres: received honoraria from Janssen‐Cilag, Sanofi‐Aventis and Johnson & Johnson. SH has accepted travel or hospitality payment from Janssen‐Cilag, Sanofi‐Aventis, Johnson & Johnson, Pfizer, Bristol‐Myers Squibb, AstraZeneca, Lundbeck, Novartis and Eli Lilly.
Werner Kissling: has received honoraria for board memberships, consulting and lectures from Janssen and Eli Lilly; honoraria for development of educational materials from Janssen; grant support from Janssen and AstraZeneca; and travel/accommodation expenses from AstraZeneca, Eli Lilly and Janssen.
John M Davis: none to declare.
Acknowledgements
We thank the editorial team of the Cochrane Schizophrenia Group for its enormous support. We thank Richard Skodnek, MD, for his work on a preliminary version of this review. We also thank Astellas, Bristol MyersSquibb, EliLilly, Lundbeck, Pfizer, Johnson & Johnson, SanofiAventis, Eric Chen, George Gardos, Julian Leff, and Erik Denys for sending additional information on their studies. We thank Michael Borenstein and Georgia Salanti for their statistical advice and for conducting statistical analyses.
The Cochrane Schizophrenia Group Editorial Base in Nottingham, UK, produces and maintains standard text for use in the Methods section of their reviews. We have used some of this text as the basis of what appears here and adapted it as required.
Version history
| Published | Title | Stage | Authors | Version |
| 2020 Aug 11 | Maintenance treatment with antipsychotic drugs for schizophrenia | Review | Anna Ceraso, Jessie Jingxia LIN, Johannes Schneider-Thoma, Spyridon Siafis, Magdolna Tardy, Katja Komossa, Stephan Heres, Werner Kissling, John M Davis, Stefan Leucht | |
| 2012 May 16 | Maintenance treatment with antipsychotic drugs for schizophrenia | Review | Stefan Leucht, Magdolna Tardy, Katja Komossa, Stephan Heres, Werner Kissling, John M Davis | |
| 2009 Oct 07 | Maintenance treatment with antipsychotic drugs for schizophrenia | Protocol | Katja Komossa, Anna M Depping, Stephan Heres, Werner Kissling, John M Davis, Stefan Leucht | |
Differences between protocol and review
Instead of Stata 2002 we used Comprehensive Meta‐analysis Version 2 (Borenstein 2006) for the meta‐regression, but both programs use the same formulae. NNTB and NNTH were calculated as the inverse of the risk difference rather than using Visual Rx. Various subgroup and meta‐regression analyses were added and the method section on the investigation of heterogeneity changed to reflect this. Post‐hoc analyses were clearly marked as such using an asterisk*.
We only contacted the manufacturers of so‐called second‐generation antipsychotic drugs for further trials (Sanofi‐Aventis, Astellas, Bristol‐Myers Squibb, Novartis, Eli Lilly, AstraZeneca, Janssen‐Cilag, Lundbeck and Pfizer; asenapine, iloperidone and lurasidone were not available at the time of our first search and therefore not contacted). Our attempts to contact the manufacturers of old "first‐generation antipsychotic drugs" had not been successful and most of these trials had been published more than 15 years ago (the official time trial documents must be stored in many countries).
